Treatment of cutaneous lichen planus (part 2): a review of systemic therapies

Abstract

Background: Although numerous medications are available for the treatment of cutaneous lichen planus (CLP), recurrence is common and there is a lack of evidence of efficacy of many treatment options. Part 1 reviewed consolidated evidence from topical therapies and phototherapy. In Part 2, all systemic treatments are assessed.

Methods: All English studies, regardless of design, investigating the outcome of systemic treatment for CLP, until January 2018, were included. While there were only a few well-designed randomized control trials (RCTs), evidence was extrapolated and graded from open trials, case series as well as case reports.

Results: Mini pulse therapy with corticosteroids should be considered over moderate daily dosing with retinoids being an alternative option. Low-dose methotrexate is considered effective and safe provided it is regularly monitored. Azathioprine, cyclosporine and mycophenolate mofetil require larger more defined RCTs in resistant CLP. Low-molecular-weight heparins may be considered in patients with no response to first-line treatment. Biologics are potentially promising but there is a need for RCTs with a considerable duration to determine their long-term safety profiles. Evidence with various other drugs were reported.

Conclusion: Clinicians may have a broader perspective on the efficacy of treatments across all study profiles.

Keywords:

• Cutaneous lichen planus
• systemic treatment
• review

Disclosure statement

No potential conflict of interest was reported by the authors.